FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202291872> ?p ?o ?g. }

• W3202291872 endingPage "e002484" @default.
• W3202291872 startingPage "e002484" @default.
• W3202291872 abstract "Introduction Here we report the glycemic efficacy and safety of ertugliflozin in patients in the VERTIS CV cardiovascular outcome trial with chronic kidney disease (CKD) stage 3. Research design and methods Prespecified and post-hoc analyses were performed in patients with an estimated glomerular filtration rate (eGFR) 30–<60 mL/min/1.73 m 2 at screening. The primary endpoint was glycemic efficacy at week 18. Longer term glycemic efficacy and changes in body weight, systolic blood pressure (SBP), and eGFR were also evaluated. Results Among 8246 patients in VERTIS CV, 1776 patients had CKD stage 3; 1319 patients had CKD stage 3A (eGFR 45–<60 mL/min/1.73 m 2 ); 457 patients had CKD stage 3B (eGFR 30–<45 mL/min/1.73 m 2 ). Week 18 least squares (LS)-mean (95% CI) placebo-adjusted changes from baseline in glycated hemoglobin (HbA1c) for 5 mg and 15 mg ertugliflozin were −0.27% (−0.37% to –0.17%) and −0.28% (−0.38% to –0.17%), respectively, for CKD stage 3 overall and −0.27% (−0.38% to –0.15%) and −0.31% (−0.43% to –0.19%), respectively, for CKD stage 3A (all p<0.001). For CKD stage 3B, the reduction in HbA1c for 5 mg ertugliflozin was −0.28% (−0.47% to –0.08%) (p=0.006) and for 15 mg ertugliflozin was −0.19% (−0.39% to 0.01%) (p=0.064). LS-mean placebo-adjusted reductions in body weight (range: −1.32 to −1.95 kg) and SBP (range: −2.42 to −3.41 mm Hg) were observed across CKD stage 3 categories with ertugliflozin. After an initial dip, eGFR remained above or near baseline with ertugliflozin treatment. The incidence of overall adverse events (AEs), symptomatic hypoglycemia, hypovolemia, and kidney-related AEs did not differ between ertugliflozin and placebo across CKD stage 3 subgroups. Conclusions In VERTIS CV patients with CKD stage 3A, ertugliflozin resulted in reductions in HbA1c, body weight and SBP, maintenance of eGFR, and was generally well tolerated. Results in the CKD stage 3B subgroup were generally similar except for an attenuated HbA1c response with the 15 mg dose. Trial registration number NCT01986881 ." @default.
• W3202291872 created "2021-10-11" @default.
• W3202291872 creator A5026935251 @default.
• W3202291872 creator A5029467844 @default.
• W3202291872 creator A5033587716 @default.
• W3202291872 creator A5038247520 @default.
• W3202291872 creator A5051174907 @default.
• W3202291872 creator A5059098934 @default.
• W3202291872 creator A5070855397 @default.
• W3202291872 creator A5071945904 @default.
• W3202291872 creator A5084634888 @default.
• W3202291872 creator A5085352453 @default.
• W3202291872 creator A5090448050 @default.
• W3202291872 date "2021-10-01" @default.
• W3202291872 modified "2023-10-16" @default.
• W3202291872 title "Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial" @default.
• W3202291872 cites W2073742622 @default.
• W3202291872 cites W2424539745 @default.
• W3202291872 cites W2500767839 @default.
• W3202291872 cites W2750589886 @default.
• W3202291872 cites W2756191633 @default.
• W3202291872 cites W2765189203 @default.
• W3202291872 cites W2769581384 @default.
• W3202291872 cites W2807732548 @default.
• W3202291872 cites W2808725516 @default.
• W3202291872 cites W2890465901 @default.
• W3202291872 cites W2904356389 @default.
• W3202291872 cites W2939222610 @default.
• W3202291872 cites W2944815545 @default.
• W3202291872 cites W2949665037 @default.
• W3202291872 cites W2984471300 @default.
• W3202291872 cites W3023840721 @default.
• W3202291872 cites W3036816724 @default.
• W3202291872 cites W3082267408 @default.
• W3202291872 cites W3088173406 @default.
• W3202291872 cites W3089283105 @default.
• W3202291872 cites W3092379111 @default.
• W3202291872 cites W3092434593 @default.
• W3202291872 cites W3111736005 @default.
• W3202291872 cites W3135510359 @default.
• W3202291872 cites W3159771686 @default.
• W3202291872 cites W4237332786 @default.
• W3202291872 cites W4246340431 @default.
• W3202291872 cites W4256659255 @default.
• W3202291872 doi "https://doi.org/10.1136/bmjdrc-2021-002484" @default.
• W3202291872 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8499340" @default.
• W3202291872 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34620621" @default.
• W3202291872 hasPublicationYear "2021" @default.
• W3202291872 type Work @default.
• W3202291872 sameAs 3202291872 @default.
• W3202291872 citedByCount "10" @default.
• W3202291872 countsByYear W32022918722022 @default.
• W3202291872 countsByYear W32022918722023 @default.
• W3202291872 crossrefType "journal-article" @default.
• W3202291872 hasAuthorship W3202291872A5026935251 @default.
• W3202291872 hasAuthorship W3202291872A5029467844 @default.
• W3202291872 hasAuthorship W3202291872A5033587716 @default.
• W3202291872 hasAuthorship W3202291872A5038247520 @default.
• W3202291872 hasAuthorship W3202291872A5051174907 @default.
• W3202291872 hasAuthorship W3202291872A5059098934 @default.
• W3202291872 hasAuthorship W3202291872A5070855397 @default.
• W3202291872 hasAuthorship W3202291872A5071945904 @default.
• W3202291872 hasAuthorship W3202291872A5084634888 @default.
• W3202291872 hasAuthorship W3202291872A5085352453 @default.
• W3202291872 hasAuthorship W3202291872A5090448050 @default.
• W3202291872 hasBestOaLocation W32022918721 @default.
• W3202291872 hasConcept C126322002 @default.
• W3202291872 hasConcept C126894567 @default.
• W3202291872 hasConcept C134018914 @default.
• W3202291872 hasConcept C142724271 @default.
• W3202291872 hasConcept C159641895 @default.
• W3202291872 hasConcept C204787440 @default.
• W3202291872 hasConcept C27081682 @default.
• W3202291872 hasConcept C2777180221 @default.
• W3202291872 hasConcept C2777538456 @default.
• W3202291872 hasConcept C2778653478 @default.
• W3202291872 hasConcept C2780473172 @default.
• W3202291872 hasConcept C555293320 @default.
• W3202291872 hasConcept C71924100 @default.
• W3202291872 hasConcept C90924648 @default.
• W3202291872 hasConceptScore W3202291872C126322002 @default.
• W3202291872 hasConceptScore W3202291872C126894567 @default.
• W3202291872 hasConceptScore W3202291872C134018914 @default.
• W3202291872 hasConceptScore W3202291872C142724271 @default.
• W3202291872 hasConceptScore W3202291872C159641895 @default.
• W3202291872 hasConceptScore W3202291872C204787440 @default.
• W3202291872 hasConceptScore W3202291872C27081682 @default.
• W3202291872 hasConceptScore W3202291872C2777180221 @default.
• W3202291872 hasConceptScore W3202291872C2777538456 @default.
• W3202291872 hasConceptScore W3202291872C2778653478 @default.
• W3202291872 hasConceptScore W3202291872C2780473172 @default.
• W3202291872 hasConceptScore W3202291872C555293320 @default.
• W3202291872 hasConceptScore W3202291872C71924100 @default.
• W3202291872 hasConceptScore W3202291872C90924648 @default.
• W3202291872 hasIssue "1" @default.
• W3202291872 hasLocation W32022918721 @default.
• W3202291872 hasLocation W32022918722 @default.
• W3202291872 hasLocation W32022918723 @default.

• next